Case series of nebulizing r‐tPA for COVID‐19 induced acute respiratory distress syndrome

Abstract

Abstract Fibrin deposition in the alveolar spaces during pulmonary involvement of COVID‐19 impairs the O2/CO2 exchange and leads to respiratory symptoms. In this report, Recombinant Tissue Plasminogen Activator (r‐tPA) has been nebulized to 3 critically ill COVID‐19 patients in order to resolve the deposited fibrin while avoiding the risk of bleeding. Based on these observations, nebulization of r‐tPA may be a potential therapeutic approach and new area of research for future studies.

Keywords

• ARDS
• COVID‐19
• fibrinolysis
• recombinant tissue plasminogen activator
• r‐tPA